Cell replacement therapies require clinically safe stem cells that can be used to generate many (possibly all) types of cells.
Not exact matches
Our research goal is to understand the molecular and cellular events
required for pancreatic β -
cell regeneration, and apply this knowledge towards the development of
cell replacement therapies for diabetes.
In addition, the funding will be used to support other operations including the continued development of the PEC - Encap ™ product candidate, ViaCyte's stem
cell - derived islet
replacement therapy that is being developed as a treatment for all diabetes patients who
require insulin to control their disease.
The PEC - Encap (also known as VC - 01) product candidate is designed to deliver stem
cell - derived islet
replacement therapies to patients with type 1 diabetes as well as patients with type 2 disease that
require insulin.